Therapeutic options for sarcoidosis: new and old.
The treatment of patients with sarcoidosis remains an important part of management. The role of corticosteroids has been questioned by some, while others have reported its value even in asymptomatic patients with interstitial lung disease. Cytotoxic agents have become standard therapy for some forms of chronic disease. Newer agents that modulate the immune response have been studied. A key cytokine in chronic sarcoidosis appears to be tumor necrosis factor. Drugs that inhibit its release or block its effect have been reported as effective for sarcoidosis.
Baughman
Robert P
RP
University of Cincinnati Medical Center, Interstitial Lung Disease and Sarcoidosis Clinic, Cincinnati, Ohio 45267-0565, USA. bob.baughman@uc.edu
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D018450:Disease Progression; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D008911:Minocycline / Q000627:therapeutic use; D015656:Respiratory Mechanics / Q000187:drug effects; D012507:Sarcoidosis / Q000188:drug therapy* / Q000503:physiopathology; D017565:Sarcoidosis, Pulmonary / Q000188:drug therapy; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology
D000276:Adjuvants, Immunologic; D000900:Anti-Bacterial Agents; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D008911:Minocycline; D001379:Azathioprine; D008727:Methotrexate